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ABSTRACT
Objectives: We examined whether apparent
redundancy in a cumulative meta-analysis of trials is
justified by concern about bias, random error or
generalisability of the results.
Design: Cumulative meta-analysis, risk of bias
assessment, trial sequential analysis, description of
study participants over time and a review of rationales
for conducting trials.
Data source: 126 randomised trials included in a
systematic review assessing of tranexamic acid on
blood transfusion in surgery.
Results: The cumulative meta-analysis including all
trials shows that the pooled estimate first reached
statistical significance after the second trial in 1993.
When the analysis was limited to the 38 high-quality
trials and adjusted to account for potential
systematic and random errors, the uncertainty was
resolved after the 22nd trial in 2008. When the
analysis was restricted to the two high-quality,
prospectively registered trials, the cumulative z-curve
crossed p=0.05 but not the monitoring boundary,
suggesting an early potentially spurious statistically
significant result. As precision of the pooled
estimate increased, the number of trials initiated
increased, although trial activity appeared to move to
other surgery types. Most (62%) reports cited at
least one systematic review. Of 118 reports
examined, concern about generalisability was the
reason for initiating the trial in 60%. Other reasons
were to address a question other than the effect on
bleeding (26%) and to confirm previously observed
results (4%). Unawareness of previous research was
apparent in 4% trials, while the rationale was
unclear in 3%.
Conclusions: Our results indicate that poor quality
is a more important cause of redundant research
than the failure to review existing evidence.
Concerns about generalisability of results is the main
motivation for new trials. Contrary to previous
claims, our results suggest that systematic reviews
showing treatment effects can stimulate an increase
in trial activity rather than reduce it.
INTRODUCTION
Results from cumulative meta-analyses are
often cited as proof that many researchers
fail to systematically review the evidence from
existing trials before initiating new trials.
For example, a cumulative meta-analysis of
aprotinin in cardiac surgery1 showed that
trials were initiated long after the pooled
estimates showed a statistically signiﬁcant
effect. Commenting on the paper, Chalmers2
observed that it “compellingly demonstrates why
all new research—whether basic or applied—
should be designed in the light of scientiﬁcally
defensible syntheses of existing research evidence,
and reported setting the new research ‘in the light
of the totality of the available evidence’”. Similar
conclusions have been made on the basis of
other cumulative meta-analyses.3–5
When the apparently redundant aprotinin
trials were conducted, systematic reviews were
relatively uncommon and failure to review
the previous trials was a plausible
Strengths and limitations of this study
▪ The results are based on data from a comprehen-
sive and up-to-date systematic review of trials
assessing the effect of tranexamic acid (TXA) in
all surgery types.
▪ The results challenge the view that the failure to
systematically review existing evidence is the
main cause of research redundancy.
▪ The examination of reasons for initiating new
trials is based on the rationales given in the trial
reports which may not accurately reflect the
rationale.
▪ The results are based on trials of TXA in surgery,
and although the extent to which the findings
apply to other topics is questionable, similar
observations have been made elsewhere.
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explanation for the redundancy. However, given the
increase in published reviews and their easy availability,
lack of awareness of what has gone before is nowadays a
less credible explanation for redundancy. We found that
seemingly redundant trials of the effect of tranexamic
acid (TXA) on blood transfusion were conducted even
though many of them cited a systematic review conclud-
ing that the uncertainty had been resolved.6 Habre et al7
found that 73% of trials of an anaesthetic intervention
cited a systematic review showing that the uncertainty
about its effects had been resolved. They also observed
that the number of new trials increased after publication
of the review and suggested that the strong pressure to
publish and the failure of ethics committees to ensure
the clinical relevance of new trials could be the main
reasons.
We considered two alternative explanations for the
apparent redundancy. First, the trialists may be sceptical
about the results of even seemingly conclusive reviews.
Such scepticism may arise from concerns about system-
atic or random errors distorting the results. Poor-quality
trials can introduce bias and multiple statistical testing as
new trials accumulate may increase the risk of false-
positive results. Second, even in the absence of substan-
tial bias or random error, there may be a reluctance to
generalise trial results to different patient groups. If this
were the case, strong evidence of a treatment effect
might be expected to lead to more trial activity rather
than less, as researchers examine the impact of patient
or intervention characteristics on the results.
We used data from a cumulative meta-analysis of trials
examining the effect of TXA on blood transfusion in
surgery, to explore whether deﬁciencies in the quality of
the evidence justify the continuation of trial activity. We
explored the impact of trial quality on effect estimates
and used trial sequential analysis to quantify required
information sizes and construct monitoring boundaries
to assess the risk of random error affecting the cumula-
tive estimate. We examined whether patient character-
istics changed over time and the reasons given by the
trial investigators for conducting their trial.
METHODS
Systematic review
We extracted data from trials included in our previous
systematic review of TXA for surgical bleeding. The
methods used to identify trials are described in detail
elsewhere.6 Brieﬂy, we searched for all randomised con-
trolled trials comparing TXA with placebo or a
no-treatment control. We searched the Cochrane central
register of controlled trials, MEDLINE, EMBASE and
the WHO International Clinical Trials Registry Platform,
using a combination of subject headings and text words
to identify randomised controlled trials of any antiﬁbri-
nolytic drug (see online supplementary ﬁle for
MEDLINE search strategy). We updated our searches to
May 2014 to incorporate trials published since the
original version of the review. Data were extracted on
patient characteristics, type of surgery and the number
of patients who received a blood transfusion. We used
the Cochrane’s tool for assessing risk of bias in the
included trials.8 We assessed the risk of bias associated
with the method of sequence generation, allocation con-
cealment, blinding and the completeness of outcome
data. Trials were rated as being at high, low or unclear
risk of bias for each domain. We considered trials with
adequate allocation concealment and blinded outcome
assessment to be at low risk of bias.
Analysis
Systematic review and meta-analyses
We calculated risk ratios (RRs) and 95% CIs to assess
the effect of TXA on blood transfusion. We pooled the
data in a ﬁxed-effect cumulative meta-analysis based on
date of publication. We conducted separate meta-analysis
for all trials, trials at low risk of bias and trials at low risk
of bias that had prespeciﬁed blood transfusion as
outcome on a registration record.
Trial sequential analyses
We used trial sequential analyses (TSA) to examine the
reliability of the cumulative meta-analysis. TSA involves
calculating the number of participants (ie, information
size) required before the result of a meta-analysis can be
considered reliable and constructs statistical monitoring
boundaries to account for type I and II errors due to
multiple testing.9 We conducted three analyses: (1) all
trials, (2) trials at low risk of bias and (3) prospectively
registered, low risk of bias trials with blood transfusion
as a prespeciﬁed outcome. We calculated the required
meta-analysis information size assuming a type I error of
5% and 90% power, a baseline event rate of 40% and a
relative risk reduction of 15%. We chose a relative risk
reduction of 15% as we judged this to represent a min-
imally clinical important effect. The estimate was
adjusted for maximum anticipated heterogeneity of
I2=75%.
We used Microsoft Excel, STATA V.13,10 RevMan
V.5.311 and the TSA Software V.0.9 β12 for the analyses.
To explore the hypothesis that reliable demonstration
of a treatment effect leads to an increase in trial activity,
we plotted the precision of the pooled effect estimate
(described by the SE of the cumulative pooled RR)
against the number of new trials initiated (deﬁned as
start date of recruitment) per year. We did this both for
all trials and for the subset of cardiac surgery trials.
We also plotted the publication date of each trial strati-
ﬁed by surgery type.
We examined trial reports to explore the reasons
given for trial initiation and categorised the reasons into
main themes.
Finally, we explored how the size and quality of trials
changed over time. We compared the mean sample size
and the proportion of trials at low risk of bias that were
published before and after the Cochrane systematic
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review by Henry et al.13 This systematic review was
chosen as it was the ﬁrst and most comprehensive review
conducted on the effect of TXA in surgical bleeding.
The review was published in October 1999. We allowed
for a 5-year time lag for the results of the review to have
an impact on published research and compared trials
published before and after 1 November 2004.
RESULTS
Systematic review and meta-analyses
We found 126 trials with 12 429 patients of the effect of
TXA on blood transfusion in surgery with data suitable
for analysis. One hundred and twenty trials (95%) were
conducted in a single centre. The median sample size
was 79 patients (range 10–660). The trials involved
cardiac (n=51), orthopaedic (n=49), obstetric and
gynaecological (n=10), cranial (n=9), urological (n=3),
hepatic (n=2), vascular (n=1) and abdominal (n=1) pro-
cedures. Thirty-eight (30%) trials had adequate alloca-
tion concealment and blinded outcome assessment and
were considered at low risk of bias. We identiﬁed a clin-
ical trial registration record for 24 (19%) trials. Six (5%)
trials had been prospectively registered, four (3%) of
which had prespeciﬁed blood transfusion as an outcome
and two of these (2%) were at low risk of bias. Allowing
for a 12-month publication time lag, 110 of the 118
(93%) trial reports published as journal articles were
published when at least one systematic review was avail-
able. Examination of the reference lists showed that 68
(62%) cited one of the available systematic reviews.
Based on all 126 included trials, TXA administration
appeared to reduce the risk of receiving a blood transfu-
sion by 38% (pooled RR=0.62; 0.59 to 0.65; p<0.0001).
The cumulative estimate was statistically signiﬁcant
(p<0.05) after the second trial (published in August
1993) and remained so thereafter. Based on data from
the 38 trials at low risk of bias, TXA appeared to reduce
the risk of receiving a blood transfusion by 32% (pooled
RR=0.68; 0.63 to 0.73; p<0.001). The cumulative estimate
was ﬁrst statistically signiﬁcant after the fourth high-
quality trial but remained statistically signiﬁcant after the
sixth trial. When the analysis was limited to the two low
risk of bias, prospectively registered trials that prespeci-
ﬁed blood transfusion as an outcome measure, TXA
appeared to reduce the risk of transfusion by 21%
(pooled RR=0.79; 0.71 to 0.87; p<0.001).
Trial sequential analyses
Figure 1 shows the results of the TSA. The required
information size was estimated at 10 888 patients.
Based on data from all 126 trials, there appears to be
strong evidence that TXA reduces the risk of blood
transfusion in surgery. The z-curve crosses the monitor-
ing boundary before the heterogeneity-adjusted informa-
tion size is achieved when the 28th trial was published in
March 2001. Prior to this point, there were 26
potentially spurious p values. Since the monitoring
boundary was crossed, a further 98 trials have been
published.
Based on the 38 low risk of bias trials, there appears
to be strong evidence that TXA reduces blood transfu-
sion. The z-curve crosses the monitoring boundary after
the 22nd high-quality trial published in November
2008. Prior to this point, there were 18 potentially
spurious p values. Since the monitoring boundary was
crossed, a further 15 high-quality trials have been
published.
When the analysis is restricted to the two low risk of bias
trials which had prespeciﬁed blood transfusion as an
outcome, the z-curve does not cross the monitoring
Figure 1 Results of trial sequential analyses for (A) all trials,
(B) trials at low risk of bias and (C) low risk of bias trials with
transfusion prespecified on prospective registration record. For
each analysis an information size is calculated on the basis
assuming α=5%, β=10%, control group event rate of 40%,
relative risk reduction of 15% and anticipated maximum
heterogeneity of I2=75%. The solid black line illustrates the
cumulative z-curve, the solid grey line shows the trial
sequential monitoring boundary.
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boundary and the heterogeneity-adjusted information size
is not achieved. There is one potentially spurious p value.
Figure 2 shows the precision of the cumulative pooled
estimate (SE of the log cumulative RR) and the number
of trials initiated per year from 1991 to 2014. As the pre-
cision of the pooled estimate increases (ie, decrease in
the SE), the number of new trials initiated each year
also increases. A similar pattern is observed for trials in
cardiac surgery (ﬁgure 3).
Figure 4 shows a timeline of the publication of the
trials, stratiﬁed by surgery type. It appears that trials
were ﬁrst conducted in cardiac surgery and shortly after-
wards in orthopaedic surgery. Trial activity then expands
to other types of surgery namely cranial, urological and
gynaecological surgery.
Qualitative review of trial justifications
Eight trials were reported in abstract or summary form
only, leaving 118 trials reported in sufﬁcient detail to
extract information on the rationale. A summary of the
extracted information is shown in table 1. Concerns
about the generalisability of the available evidence was
used to justify 71 (60%) trials. These trials sought to rep-
licate a previously observed beneﬁcial effect of TXA on
surgical bleeding but in a different group of patients,
such as those undergoing a different type of surgical
procedure. Thirty-one (26%) trials were initiated to
answer a different research question to the effect of
TXA on bleeding. Most of these trials were conducted
to examine the effect of different doses or timings of
TXA despite the inclusion of a placebo or no-TXA
Figure 3 Precision of the cumulative pooled estimates for the effect of tranexamic acid in cardiac surgery described by the SE
of the risk ratios (RRs; left hand axis) and the number of trials (5-year moving averages, right hand axis) initiated per year.
Figure 2 Precision of the cumulative pooled estimates described by the SE of the risk ratios (RRs; left hand axis) and the
number of trials (5-year moving averages, right hand axis) initiated per year.
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control group. Five (4%) trials appeared to have been
conducted because of a failure to synthesise prior evi-
dence. The trial rationale was unclear in 4 (4%) trials.
Comparison of trials conducted before and after
publication of the Henry et al systematic review
Of the 126 trials, 47 (37%) were published before 1
November 2004 compared with 79 (63%) published
afterwards up to May 2014. The average sample size had
increased between the two periods (mean±SD, 64±50 vs
119±103; p<0.0001). A larger proportion of trials pub-
lished after November 2004 were judged to be at low
risk of bias for both allocation concealment and blind-
ing (12 (26%) vs 28 (35%); p=0.23).
DISCUSSION
Principal findings
We examined two hypotheses for the redundancy in a
cumulative meta-analysis. First, that despite the appar-
ently conclusive results, legitimate concerns about bias
and random error justiﬁed new trials. We found some
support for this. Most trials were small, single centre, low
quality and hardly any were prospectively registered.
Nevertheless, when only high-quality trials were consid-
ered, with steps taken to reduce the risk of false-positive
results, there remained strong evidence that TXA
reduces transfusion.
Our second hypothesis was that new trials are con-
ducted because of concerns about the generalisability of
the results. We found strong support for this. Increasing
evidence that TXA decreases the need for blood transfu-
sion resulted in more trial activity and not less. The
change in patient characteristics over time and the ratio-
nales given by trialists also indicate that generalisability
concerns motivated the new trials. That over half of
trials cited at least one of the existing systematic reviews
suggests that ignorance of the existing evidence does not
fully explain ongoing trial activity.
The average sample size of trials has increased, and
there is some suggestion that the quality of trials has
improved over time.
Strengths and weaknesses
We examined trial reports to ﬁnd the reasons authors
gave for conducting new trials. This process was inevit-
ably subjective and different assessors might have made
different judgements. Furthermore, trial reports might
not accurately reﬂect the rationale at trial inception. We
did not contact authors, although whether this would
have provided more reliable information is uncertain.
There are other, non-scientiﬁc motivations, such as mon-
etary and academic, for initiating a new trial which
would not be publically reported. Nevertheless, the
reasons given in trial reports are the openly given justiﬁ-
cations that are accepted by the scientiﬁc community
and are therefore a reasonable focus for review.
Our study was based on clinical trials of TXA in
surgery, and the extent to which the results apply to
other topics is questionable. However, we have also
Figure 4 Timeline of publication of trials of TXA stratified by type of surgery (TXA, tranexamic acid; O&G, obstetric and
gynaecological).
Table 1 Summary of reasons for initiating trials of tranexamic acid for surgical bleeding based on information extracted from
the final reports
Failure to
synthesise
evidence Confirmatory Generalisability
Assessing a different
research question Unclear
Trials citing ≥1 available
systematic review (n=68)
– 2 51 11 4
Trials not citing an available
systematic review (n=42)
2 3 21 16 –
Trials published before a
systematic review was
available (n=9)
3 – – 6 –
All trial reports (n=118) 5 (4%) 5 (4%) 72 (61%) 33 (28%) 4 (3%)
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found that publication of a systematic review showing
strong evidence that TXA reduces mortality in bleeding
trauma patients also resulted in increased trial activity
rather than less. A 2004 systematic review of TXA in
acute traumatic injury14 found no eligible trials even
though TXA was commonly used in other bleeding con-
ditions. The review prompted the Clinical
Randomisation of an Antiﬁbrinolytic in Signiﬁcant
Haemorrhage (CRASH-2) trial which included 20 211
bleeding trauma patients and showed that TXA reduces
death due to bleeding and all-cause mortality.15 The sub-
sequently updated review included two trials and
reported that the uncertainty had been resolved.16
Nevertheless, some authors, pointing out that many of
the patients in the CRASH-2 trial were recruited from
hospitals in Africa, Asia and Latin America, questioned
whether the results can be applied in ‘modern’ trauma
care systems17 and have initiated new clinical trials
rather than implementing the results.18 19 Although sub-
group analyses show that the CRASH-2 trial results do
not vary by geographical region,20 two placebo-
controlled trials are underway.14 15 Habre et al7 also
found that publication of a conclusive review coincided
with increased trial activity and that most new trials cited
the conclusive review.
There are other potential explanations for the con-
tinuation of trial activity that we have not explored.
Habre et al suggested that redundant trials of an anaes-
thetic intervention may have been motivated by the self-
interest of researchers wishing to gain more research
publications. In relation to our study, trials of the effect
of TXA on blood transfusion are relatively easy to
conduct, and since a treatment effect is highly likely, it
would be an attractive topic for research.
Implications
Our results raise questions about the process of scientiﬁc
generalisation. If there is strong evidence that TXA
reduces bleeding in cardiac and orthopaedic surgery, is
it necessary to examine its effect in obstetric surgery?
Rothman et al21 argues that the reluctance to generalise
results to populations that were not represented in the
original research confuses statistical and scientiﬁc infer-
ence. Statistical inference, the process of using sample
information to reach conclusions about the population
from which it was drawn, is helped by having a represen-
tative sample. However, generalising trial results involves
scientiﬁc inference, a process of reaching general con-
clusions about how a treatment works. The main pre-
requisite for scientiﬁc inference is a biological insight
into the mechanism of action of the treatment and an
awareness of the circumstances that may be relevant to
this mechanism. Rather than using statistical reasoning,
it is more appropriate to use biological reasoning and
ask whether there is any good reason why TXA would
work differently in orthopaedic or urological surgery?
A further concern is the number of inappropriately
designed trials. This typically concerns trials which
aimed to build on the existing knowledge by comparing
different doses or timings of TXA, yet opted to include
a no-treatment comparison group. The inclusion of a
no-treatment comparison group in such trials is wasteful
and unethical—failings that implicate both trialists and
the ethical review committees approving the trials. In
this article, we focus on the potential explanations for
trialists’ decision to initiate further trials of TXA, yet
there is also a question regarding why patients continue
to agree to participate in apparently ‘redundant’ trials in
which there is a chance they will forego receiving an
effective treatment. We did not attempt to obtain the
patient information sheets used in the trials, and there
remains an unanswered question regarding the extent to
which trial participants are made aware of the existing
evidence as part of the consent giving process.
Our results suggest that low-quality trials are a more
important cause of ‘research waste’ than the failure to
systematically review the existing evidence. When only
high-quality trials are considered, the number of statistic-
ally ‘redundant’ trials was reduced from 98 to 15. Most
trial reports clearly indicated an awareness that TXA
had been shown to reduce bleeding but sought to
examine its effect in different types of surgery. For this
reason, more systematic reviews and greater attention to
existing reviews will only increase research waste unless
determined efforts are made to increase quality in the
form of adequately powered trials that are properly ran-
domised with adequate allocation concealment and
blinding.
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